Meeting
2015 ASCO Annual Meeting
FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type.
Authors
Yanhong Deng
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Yanhong Deng , Huabin Hu , Guanjian Liu , Yue Cai , Jianwei Zhang , Meijin Huang , Lei Wang , Lan Ping , Jianping Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT02350530
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS3624)
DOI
10.1200/jco.2015.33.15_suppl.tps3624
Abstract #
TPS3624
Poster Bd #
115a
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial.
First Author: Shahid Ahmed
Poster
2013 ASCO Annual Meeting
Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA.
First Author: Thomas Gruenberger
Poster
2020 Gastrointestinal Cancers Symposium
Rate of conversion from unresectable to resectable metastatic colorectal cancer (mCRC) in real-world patients (RWP) treated with FOLFIXIRI ± bevacizumab: A population-based retrospective cohort study.
First Author: Tayyaba Bhatti
Poster
2015 Gastrointestinal Cancers Symposium
Folfoxiri with or without cetuximab as first-line treatment of patients with non-resectable liver, only metastatic colorectal cancer and KRAS/NRAS wild type (FOCULM study).
First Author: Yanhong Deng